Amsterdam, 27 February 2025
EMA/CMDh/59625/2025
Co-ordination group for Human Use (CMDh)
PSUSA/00002942/202406

Position of the Co-ordination Group for Mutual Recognition and Decentralised Procedures for human use on Periodic Safety Update Reports for

Active substance(s): tiagabine

Nationally authorised Medicinal product(s): See PRAC PSUR Assessment Report appendix

Basis for position

Pursuant to Article 107b of Directive 2001/83/EC, the Marketing Authorisation Holder(s) for nationally authorised medicinal products (for details see PRAC PSUR Assessment report) submitted to the European Medicines Agency periodic safety update reports (PSURs) for the medicinal products containing the above referred active substance(s).

The evaluation procedure started on 17 October 2024.

The steps taken for the assessment of the PSURs are detailed in the appended Pharmacovigilance Risk Assessment Committee (PRAC) assessment report.

The recommendation was adopted by the PRAC on 13 February 2025.

Position

1. The CMDh, having considered in accordance with Article 107g(1) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, reaches its position by consensus, on the variation to the terms of the Marketing Authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

   Update of section 4.9 of the SmPC to add loss of consciousness and confusional state as symptoms in a context of overdose. The Package leaflet is updated accordingly.

   The Icelandic, of Liechtenstein and the Norwegian CMDh member(s) agree(s) with the above-mentioned position of the CMDh.

2. The scientific conclusions are set out in Annex I.

3. The amendments to be introduced to the product information of the medicinal products containing the above referred active substance(s) are set out in Annex II.

4. The timetable for the implementation of this CMDh position is set out in Annex III.

To the extent that other medicinal products containing tiagabine not listed in the PRAC assessment report are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and Marketing Authorisation Holders take due consideration of this CMDh position.

This position is forwarded, to Member States, to Iceland, Liechtenstein and Norway, to the MAHs together with its annexes and appendix(ces).

Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for tiagabine, the scientific conclusions are as follows:

In view of available data on tiagabine overdose from spontaneous reports, the PRAC considers a causal relationship between tiagabine and loss of consciousness or confusional state in a context of overdose is at least a reasonable possibility. The PRAC concluded that the SmPC and PL of products containing tiagabine should be amended accordingly.

Having reviewed the PRAC recommendation, the CMDh agrees with the PRAC overall conclusions and grounds for recommendation.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for tiagabine the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing tiagabine is unchanged subject to the proposed changes to the product information

The CMDh recommends that the terms of the marketing authorisation(s) should be varied.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.9

Symptoms most often accompanying {X} overdose, alone or in combination with other medicinal products, have included seizures, including status epilepticus, in patients with and without underlying seizure disorders, mute and withdrawn appearance of the patient, amnesia, coma, **loss of consciousness**, spike wave stupor, encephalopathy, **confusional state**, somnolence, dyskinesia, myoclonus, tremors, ataxia or incoordination, dizziness, impaired speech, hostility, agitation, vomiting~~, and~~**. R**espiratory depression has been seen in the context of seizures.

Package Leaflet

- 3. How to take {X}

[…] **If you take more {X} than you should**

The most common symptoms of overdose with {X} are seizures, mute (silent) and withdrawn**, loss of consciousness**, loss of memory, coma, difficulty coordinating movements, sleepiness, dizziness, confusion, impaired speech, agitation, tremors, abnormal involuntary movements (dyskinesia), involuntary contraction of muscles, vomiting and hostility.

If you have taken too many tablets or if a child has taken any, immediately contact your doctor or the nearest hospital. […]

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	February 2025 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	13 April 2025
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	12 June 2025

APPENDIX I

PRAC PSUR Assessment Report